Looking ahead, Morgan Stanley expects PB Fintech's stock to de-rate as core new business performance moderates in FY26.
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
Morgan Stanley closed $12.79 short of its 52-week high ($136.24), which the company achieved on November 25th.
Aditya Birla Capital shares rose 3.5% after Morgan Stanley upgraded the stock to 'overweight' with a target price of Rs 247, ...
While Citi, BofA and Goldman touted their biggest cohorts of managing directors in years, Morgan Stanley elevated greater ...
The popularity of alcohol-free Guinness won’t protect the shares of its owner Diageo Plc from the growing trend toward health ...
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate ...
Morgan Stanley upgraded AB Capital to "overweight" from "equal-weight" and set a target price of Rs 247 per share ...
Robert Chen and his team like strategies like direct indexing because they systematically tax loss harvest throughout the ...